From High Risk to Movable Risk: Can Health Plans Change the Cardiometabolic Trajectory?
Health plans are increasingly good at identifying cardiometabolic risk. The harder question is which risk is actually movable, and where intervention can materially change disease progression, utilization and cost.
This Bright Spots in Healthcare discussion will examine how leading plans are prioritizing the members and opportunities with the greatest potential for impact, determining which interventions are producing meaningful clinical and economic value, and deciding what evidence is strong enough to justify continued investment and scale.
Key Takeaways
- How plans are distinguishing high-risk members from those with the greatest opportunity for meaningful intervention
- Where earlier, more targeted action can change disease progression, utilization and downstream cost
- Which outcomes best demonstrate that cardiometabolic risk is actually changing, not simply that members are engaging
- How plans are evaluating impact across clinical outcomes, medication utilization, medical spend and total cost of care
- How leaders decide which cardiometabolic strategies warrant greater investment broader deployment, or a different approach
This conversation is designed for health plan leaders responsible for population health, Medicare Advantage, clinical strategy, quality, product and innovation who are making decisions about where to focus cardiometabolic investment. If you are evaluating how to identify the members most likely to benefit, intervene earlier and demonstrate meaningful clinical and economic impact, this discussion will offer practical perspectives from peers facing the same decisions.